Follow The Filings

NAUT Nautilus Biotechnology

Nautilus Biotechnology earnings company data as of 5:00 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 27 Oct EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by NAUT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NAUT insider trades
  • $71K bought by 2 insiders
  • $11.8M sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. AH Equity Partners Bio II, L.L.C. 10% owner, +5 joint filers
    Sale
    $11.8M 5,000,000 shares at $2.35 84% of stake
    Traded Jun 2 Filed Jun 4
    ↗
  2. Sujal M Patel CEO
    Buy
    $65K 25,000 shares at $2.61 +0.2% to stake
    Traded Mar 4 Filed Mar 4
    ↗
  3. Kentaro Suzuki Chief Marketing Officer
    Buy
    $5,960 4,000 shares at $1.49 New stake
    Traded Nov 6, 2025 Filed Nov 10, 2025
    ↗

SEC filings

Recent issuer filings from EDGAR, 23 shown.

Filed Form Detail Links
424B5 Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,1.02,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13D/A — Filing Doc
DEF 14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 8.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.